Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 16, 2023
Agios Pharmaceuticals (Nasdaq: AGIO) has announced its presentation schedule at the RBC Capital Markets Global Healthcare Conference on May 16, 2024, at 9 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Agios Pharmaceuticals (Nasdaq: AGIO) has announced its presentation schedule at the RBC Capital Markets Global Healthcare Conference on May 16, 2024, at 9 a.m. ET. This conference is a key opportunity for investors and analysts to engage with the company.
Participants can access a live webcast via the Investors section of the Agios website, with an archived replay available for two weeks post-presentation. Agios is recognized for its innovative work in cellular metabolism and offers therapies for rare diseases, including a first-in-class pyruvate kinase activator for PK deficiency.
The company’s pipeline includes investigational therapies for conditions such as sickle cell disease and thalassemia, reinforcing its commitment to developing solutions for serious health challenges.
Details
News Market Reaction – AGIO
The recorded move for AGIO in the trading session of this news was -0.31%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the company is scheduled to present at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 16, 2024, at 9 a.m. ET.
A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. A replay of the webcast will be archived on the company’s website for at least two weeks following the presentation.
About Agios
Agios is a biopharmaceutical company that is fueled by connections. The Agios team cultivates strong bonds with patient communities, healthcare professionals, partners and colleagues to discover, develop and deliver therapies for rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's leadership in the field of cellular metabolism, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency and MDS-associated anemia. In addition to its clinical pipeline, Agios has a PAH stabilizer in preclinical development as a potential treatment for phenylketonuria (PKU) and deep scientific expertise in classical hematology. For more information, please visit the company’s website at www.agios.com.
Contacts:
Investor Contact
Cecilia Jones, Chief Financial Officer
Agios Pharmaceuticals
IR@agios.com
Media Contact
Dan Budwick
1AB Media
dan@1abmedia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.